Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors.

Patients with rheumatic and musculoskeletal diseases (RMDs) on immunosuppressants are considered a vulnerable group in COVID-19 pandemic and vaccination is the mainstay for the prevention of this infection (1). To date, recommendations and data for COVID-19 vaccination in adolescent patients with RMDs are lacking (2). International societies and post-authorization safety reports of the novel mRNA COVID-19 vaccines are generally reassuring; nonetheless their safely profile in adolescents with RMDs on immune-modulating treatment is unknown, since these individuals were excluded from the vaccine trials (3-5).